Cardinal Health Eyes 13–15% EPS Growth on Specialty Surge
Cardinal Health sets ambitious earnings growth targets as its specialty pharmaceutical segment gains momentum.
Cardinal Health is putting a number on its ambitions: 13% to 15% earnings-per-share growth, driven by a specialty pharmaceutical business that's clearly hitting its stride. That's not a soft guidance range — that's a statement of intent from a company that wants Wall Street to pay attention.
The specialty segment is the real story here. It's been the growth engine quietly powering Cardinal's financials, and management is now leaning into it hard enough to anchor the whole EPS outlook around it. When a healthcare distributor shifts its narrative from volume to specialty, that's a margin story worth tracking.
Read more Jim Cramer Gives Reddit Stock His Buy Endorsement →
For traders, the setup is straightforward. A double-digit EPS growth target in a sector that typically grinds out low-to-mid single digits is a differentiator. If Cardinal can execute, the stock has a credible re-rating argument — especially if specialty momentum compounds over multiple quarters rather than fading after one good print.
The risk, as always, is execution. Specialty pharma distribution is competitive, and pricing pressure never fully goes away in this industry. But the fact that Cardinal is willing to stamp a 13–15% growth rate on its outlook signals confidence from the C-suite — not wishful thinking.
Watch the next earnings print closely. If specialty revenue continues to accelerate and EPS lands in the upper half of that guidance band, Cardinal stops being a sleepy healthcare name and starts looking like a compounder. Continue reading at Yahoo Finance.
